このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

60歳以上の成人における研究中の呼吸器合胞体ウイルス(RSV)ワクチンの免疫原性、安全性、反応原性および持続性

2026年9月25日 更新者:GlaxoSmithKline

RSVPreF3 OA 治験用ワクチンの単回投与の免疫原性、安全性、反応原性、持続性、および 60 歳以上の成人におけるさまざまな再接種スケジュールを評価するための第 3 相無作為化非盲検多国試験

The purpose of this study is to assess the safety, reactogenicity, immunogenicity and long-term persistence of immune response up to 5 years following a single dose vaccination of GSK's investigational vaccine RSVPreF3 OA, in adults aged 60 years and above. The study will also evaluate the immunogenicity, safety and reactogenicity of additional vaccine doses given according to different revaccination schedules.

調査の概要

状態

積極的、募集していない

条件

介入・治療

研究の種類

介入

入学 (実際)

1720

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Mobile、Alabama、アメリカ、36608
        • GSK Investigational Site
    • Arizona
      • Phoenix、Arizona、アメリカ、85020
        • GSK Investigational Site
    • California
      • Riverside、California、アメリカ、92503
        • GSK Investigational Site
      • San Diego、California、アメリカ、92103
        • GSK Investigational Site
    • Florida
      • Coral Gables、Florida、アメリカ、33134
        • GSK Investigational Site
      • Fort Myers、Florida、アメリカ、33912-4316
        • GSK Investigational Site
      • Sarasota、Florida、アメリカ、34243
        • GSK Investigational Site
      • The Villages、Florida、アメリカ、32162
        • GSK Investigational Site
    • Indiana
      • Evansville、Indiana、アメリカ、47714
        • GSK Investigational Site
    • Kansas
      • Wichita、Kansas、アメリカ、67226
        • GSK Investigational Site
    • Minnesota
      • Richfield、Minnesota、アメリカ、55423
        • GSK Investigational Site
    • Missouri
      • Kansas City、Missouri、アメリカ、64114-4859
        • GSK Investigational Site
    • New York
      • Rochester、New York、アメリカ、14609-3173
        • GSK Investigational Site
    • South Carolina
      • Mt. Pleasant、South Carolina、アメリカ、29464
        • GSK Investigational Site
      • Spartanburg、South Carolina、アメリカ、29303
        • GSK Investigational Site
    • Texas
      • San Antonio、Texas、アメリカ、78229-6306
        • GSK Investigational Site
    • Virginia
      • Norfolk、Virginia、アメリカ、23502
        • GSK Investigational Site
    • Washington
      • Wenatchee、Washington、アメリカ、98801-2028
        • GSK Investigational Site
      • Essen、ドイツ、45355
        • GSK Investigational Site
      • Hamburg、ドイツ、20095
        • GSK Investigational Site
      • Mainz、ドイツ、55116
        • GSK Investigational Site
      • München、ドイツ、80339
        • GSK Investigational Site
      • Wallerfing、ドイツ、94574
        • GSK Investigational Site
      • Würzburg、ドイツ、97074
        • GSK Investigational Site
    • North Rhine-Westphalia
      • Essen、North Rhine-Westphalia、ドイツ、45359
        • GSK Investigational Site
      • Goch、North Rhine-Westphalia、ドイツ、47574
        • GSK Investigational Site
      • Espoo、フィンランド、02230
        • GSK Investigational Site
      • Helsinki、フィンランド、00100
        • GSK Investigational Site
      • Helsinki、フィンランド、00930
        • GSK Investigational Site
      • Jarvenpaa、フィンランド、04400
        • GSK Investigational Site
      • Kokkola、フィンランド、67100
        • GSK Investigational Site
      • Oulu、フィンランド、90220
        • GSK Investigational Site
      • Seinäjoki、フィンランド、60100
        • GSK Investigational Site
      • Tampere、フィンランド、33100
        • GSK Investigational Site
      • Turku、フィンランド、20520
        • GSK Investigational Site
    • Satakunta
      • Pori、Satakunta、フィンランド、28100
        • GSK Investigational Site
      • Changhua、台湾、500
        • GSK Investigational Site
      • Taichung、台湾、40447
        • GSK Investigational Site
      • Taichung、台湾、407
        • GSK Investigational Site
      • Taipei、台湾、100
        • GSK Investigational Site
      • Taipei、台湾、104
        • GSK Investigational Site
      • Taipei、台湾、112
        • GSK Investigational Site
      • Taoyuan、台湾、333
        • GSK Investigational Site
      • Fukuoka、日本、812-0025
        • GSK Investigational Site
      • Kumamoto、日本、861-4157
        • GSK Investigational Site
      • Tokyo、日本、160-0017
        • GSK Investigational Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

60年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

はい

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Male or female participants ≥60 YOA at first vaccination, who live in the community (CD participants) or in a Long-term care facility (LTCF participants).
  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written or witnessed informed consent obtained from the participant prior to performance of any study specific procedure.
  • Participants who are medically stable in the opinion of the investigator at the time of first vaccination. Patients with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, are allowed to participate in this study if considered by the investigator as medically stable.

Exclusion Criteria:

Medical conditions

  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy, based on medical history and physical examination.
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.
  • Hypersensitivity to latex.
  • Serious or unstable chronic illness.
  • Recurrent or un-controlled neurological disorders or seizures. Participants with medically-controlled active or chronic neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol.
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
  • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.
  • Any history of dementia or any medical condition that moderately or severely impairs cognition.

Prior/Concomitant therapy

  • Use of any investigational or non-registered product other than the study vaccine during the period beginning 30 days before the first dose of study vaccine, or planned use during the study period.
  • Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before each dose and ending 30 days after each dose of study vaccine administration, with the exception of inactivated, split virion and subunit influenza vaccines which can be administered up to 14 days before or from 14 days after each study vaccination.
  • Previous vaccination with an RSV vaccine.
  • Administration of long-acting immune-modifying drugs or planned administration at any time during the study period.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the first dose of study vaccine or planned administration during the study period.
  • Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first vaccine dose or planned administration during the study period. For corticosteroids, this will mean prednisone >=20 mg/day, or equivalent. Inhaled and topical steroids are allowed.

Prior/Concurrent clinical study experience

• Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product.

Other exclusions

  • History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
  • Bedridden participants.
  • Planned move during the study period that will prohibit participation in the trial until the study end. This includes:
  • Planned move during the study period to another LTCF that will prohibit participation in the trial until study end.
  • Planned move from the community to a LTCF that will prohibit participation in the trial until study end.
  • Participation of any study personnel or their immediate dependants, family, or household members.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:RSV_annual Group

Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and 2 revaccination doses at 12 months post-Dose 1 and at 24 months post-Dose 1, respectively and are followed up until Month 60.

RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.

実験的:RSV_Flexible revaccination Group

Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and 2 revaccination doses at 24 months post-Dose 1 and at 48 months post-Dose 1, respectively and are followed up until Month 60.

RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.

実験的:RSV_1dose Group

Participants receive one dose of RSVPreF3 OA investigational vaccine at Day 1 and are followed up until Month 36. At Month 36, participants in this group will be re-randomized in 2 groups: RSV_1dose_M36 (which will receive 1 additional revaccination dose at Month 36 and will be followed up until Month 60) and RSV_1dose_Flexible (which will receive 1 additional revaccination dose at Month 60, and will be followed up until study end at Month 72).

RSVPreF3 OA investigational vaccine administered intramuscularly in the deltoid region of the non-dominant arm.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Humoral Immune Response in Terms of Respiratory Syncytial Virus (RSV)-A Neutralizing Antibody Geometric Mean Titers (GMTs) at Day 1
時間枠:At Day 1

RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Day 1
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Day 31
時間枠:At Day 31

RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.

At Day 31
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 6
時間枠:At Month 6

RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.

At Month 6
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 12
時間枠:At Month 12

RSV-A neutralizing antibodies were given as GMTs and expressed as ED60.

At Month 12
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 1
時間枠:At Day 1

RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.

At Day 1
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Day 31
時間枠:At Day 31

RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.

At Day 31
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 6
時間枠:At Month 6

RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.

At Month 6
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 12
時間枠:At Month 12

RSV-B neutralizing antibodies measured as GMTs and expressed as ED60.

At Month 12

二次結果の測定

結果測定
メジャーの説明
時間枠
Humoral Immune Response in Terms of RSVPreF3 Immunoglobulin G (IgG) Antibody Geometric Mean Concentrations (GMCs) at Day 1
時間枠:At Day 1

Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by enzyme-linked immunosorbent assay (ELISA). The corresponding antibody GMC was expressed in Elisa Laboratory Units/milliliter (ELU/mL).

At Day 1
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Day 31
時間枠:At Day 31

Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

At Day 31
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 6
時間枠:At Month 6

Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

At Month 6
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 12
時間枠:At Month 12

Serological assays for the determination of IgG antibodies against RSV PreF3 are performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

At Month 12
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 18
時間枠:At Month 18

Month 18 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 18
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 24
時間枠:At Month 24

Month 24 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 24
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 30
時間枠:At Month 30

Month 30 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 30
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 36
時間枠:At Month 36

Month 36 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 36
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 13
時間枠:At Month 13

Month 13 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 13
Humoral Immune Response in Terms of RSV-A Neutralizing Antibody GMTs at Month 25
時間枠:At Month 25

Month 25 data will be disclosed during final posting. RSV-A neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 25
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 18
時間枠:At Month 18

Month 18 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 18
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 24
時間枠:At Month 24

Month 24 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 24
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 30
時間枠:At Month 30

Month 30 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 30
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 36
時間枠:At Month 36

Month 36 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 36
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 13
時間枠:At Month 13

Month 13 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 13
Humoral Immune Response in Terms of RSV-B Neutralizing Antibody Titers at Month 25
時間枠:At Month 25

Month 25 data will be disclosed during final posting. RSV-B neutralizing antibodies were given as GMTs and expressed as Estimated Dose: serum dilution giving a 60% reduction of the RSV plaques compared to a control without serum (ED60).

At Month 25
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 18
時間枠:At Month 18

Month 18 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

At Month 18
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 24
時間枠:At Month 24

Month 24 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

At Month 24
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 30
時間枠:At Month 30

Month 30 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

At Month 30
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 36
時間枠:At Month 36

Month 36 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

At Month 36
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 13
時間枠:At Month 13

Month 13 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

At Month 13
Humoral Immune Response in Terms of RSVPreF3 IgG Antibody GMCs at Month 25
時間枠:At Month 25

Month 25 data will be disclosed during final posting. Serological assays for the determination of IgG antibodies against RSV PreF3 were performed by ELISA. The corresponding antibody GMC was expressed in ELU/mL.

At Month 25
Cell-Mediated Immunity (CMI) Response in Terms of Frequency of RSVPreF3-specific Cluster of Differentiation CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1
時間枠:At Day 1

Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Day 1
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 1
時間枠:At Day 1

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

At Day 1
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31
時間枠:At Day 31

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

At Day 31
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Day 31
時間枠:At Day 31

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

At Day 31
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6
時間枠:At Month 6

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 6
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 6
時間枠:At Month 6

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 6
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12
時間枠:At Month 12

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 12
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 12
時間枠:At Month 12

Among markers expressed were IL2, IL13, IL17, CD40L, 41BB, TNF α and IFN γ, in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 12
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 18
時間枠:At Month 18

Month 18 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 18
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 18
時間枠:At Month 18

Month 18 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 18
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 24
時間枠:At Month 24

Month 24 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 24
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 24
時間枠:At Month 24

Month 24 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 24
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 30
時間枠:At Month 30

Month 30 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 30
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 30
時間枠:At Month 30

Month 30 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 30
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 36
時間枠:At Month 36

Month 36 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 36
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 36
時間枠:At Month 36

Month 36 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 36
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 13
時間枠:At Month 13

Month 13 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 13
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 13
時間枠:At Month 13

Month 13 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 13
CMI Response in Terms of Frequency of RSVPreF3-specific CD4 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 25
時間枠:At Month 25

Month 25 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 25
CMI Response in Terms of Frequency of RSVPreF3-specific CD8 atl2_7m T Cells Expressing at Least 2 Activation Markers at Month 25
時間枠:At Month 25

Month 25 data will be disclosed during final posting. Among markers expressed were interleukin-2/13/17 (IL2, IL13, IL17), cluster of 40 ligand (CD40L), 41BB, tumor necrosis factor alpha (TNF α) and interferon gamma (IFN γ), in vitro upon stimulation with RSVPreF3 peptide preparations.

At Month 25
Number of Participants With at Least One Solicited Administration-site Event Following Vaccination at Day 1
時間枠:During the 4-day follow up period after first vaccination (vaccine administered on Day 1)

The solicited administration-site events were erythema, pain and swelling at the injection site.

During the 4-day follow up period after first vaccination (vaccine administered on Day 1)
Number of Participants With at Least One Solicited Administration-site Event Following Vaccination at Month 12
時間枠:During the 4-day follow up period after vaccination (vaccine administered at Month 12)

Month 12 to Month 18 data will be disclosed during final posting. The solicited administration-site events were erythema, pain and swelling at the injection site.

During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Number of Participants With at Least One Solicited Administration-site Event Following Vaccination at Month 24
時間枠:During the 4-day follow up period after vaccination (vaccine administered at Month 24)

Month 24 data will be disclosed during final posting. The solicited administration-site events were erythema, pain and swelling at the injection site.

During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Number of Participants With at Least One Solicited Systemic Event Following Vaccination at Day 1
時間枠:During the 4-day follow up period after vaccination (vaccine administered on Day 1)

The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0 degree Celsius [°C]), headache and myalgia.

During the 4-day follow up period after vaccination (vaccine administered on Day 1)
Number of Participants With at Least One Solicited Systemic Event Following Vaccination at Month 12
時間枠:During the 4-day follow up period after vaccination (vaccine administered at Month 12)

Month 12 to Month 18 data will be disclosed during final posting. The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0°C), headache and myalgia.

During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Number of Participants With at Least One Solicited Systemic Event Following Vaccination at Month 24
時間枠:During the 4-day follow up period after vaccination (vaccine administered at Month 24)

Month 24 data will be disclosed during final posting. The solicited systemic events included arthralgia, fatigue, fever (defined as temperature equal to or above 38.0 degree Celsius (°C)), headache and myalgia.

During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Number of Participants With Any Unsolicited Adverse Events (AEs) Following Vaccination at Day 1
時間枠:During the 30-day follow up period after vaccination (vaccine administered on Day 1)

An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

During the 30-day follow up period after vaccination (vaccine administered on Day 1)
Number of Participants With Any Unsolicited AEs Following Vaccination at Month 12
時間枠:During the 4-day follow up period after vaccination (vaccine administered at Month 12)

Month 12 to Month 18 data will be disclosed during final posting. An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Number of Participants With Any Unsolicited AEs Following Vaccination at Month 24
時間枠:During the 4-day follow up period after vaccination (vaccine administered at Month 24)

Month 24 data will be disclosed during final posting. An unsolicited AE covers any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of study intervention, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study, and/or any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any is defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.

During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Number of Participants With Serious Adverse Events (SAE) Following Vaccination at Day 1
時間枠:From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.

From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)
Number of Participants With SAEs Following Vaccination at Month 12
時間枠:During the 4-day follow up period after vaccination (vaccine administered at Month 12)

Month 12 to Month 18 data will be disclosed during final posting. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.

During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Number of Participants With SAEs Following Vaccination at Month 24
時間枠:During the 4-day follow up period after vaccination (vaccine administered at Month 24)

Month 24 data will be disclosed during final posting. An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect in the offspring of a study participant.

During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Number of Participants Reporting Any Potential Immune-mediated Disease (pIMD) Following Vaccination at Day 1
時間枠:From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)

pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

From first vaccination (Day 1) up to 6 months post-Dose 1 (Month 6)
Number of Participants Reporting Any pIMD Following Vaccination at Month 12
時間枠:During the 4-day follow up period after vaccination (vaccine administered at Month 12)

Month 12 to Month 18 data will be disclosed during final posting. pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

During the 4-day follow up period after vaccination (vaccine administered at Month 12)
Number of Participants Reporting Any pIMD Following Vaccination at Month 24
時間枠:During the 4-day follow up period after vaccination (vaccine administered at Month 24)

Month 24 data will be disclosed during final posting. pIMDs are a subset of AEs of special interest that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune etiology.

During the 4-day follow up period after vaccination (vaccine administered at Month 24)
Number of Participants With a Fatal SAE, Related SAE and Related pIMDs
時間枠:From first vaccination (Day 1) up to study end (Month 36)

A fatal SAE is any untoward medical occurrence that results in death. A related SAE is an SAE considered to be causally related to the study intervention. A related pIMD is a pIMD considered to be causally related to the study intervention.

The study is ongoing at the time of the results posting. Results for Months 18 up to study end (Month 36) will be updated during final posting.

From first vaccination (Day 1) up to study end (Month 36)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年2月15日

一次修了 (実際)

2022年6月6日

研究の完了 (推定)

2027年2月19日

試験登録日

最初に提出

2021年1月27日

QC基準を満たした最初の提出物

2021年1月27日

最初の投稿 (実際)

2021年2月1日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月28日

QC基準を満たした最後の更新が送信されました

2026年9月25日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 212496
  • 2024-512291-34 (EudraCT番号)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

IPD for this study will be made available via the Clinical Study Data Request site.

IPD 共有時間枠

IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

IPD 共有アクセス基準

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

IPD 共有サポート情報タイプ

  • STUDY_PROTOCOL
  • SAP
  • ICF
  • CSR

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。